Status: Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).
Participants needed: 100
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Zymeworks BC Inc.Updated: May 7, 2026Locations: 25
Eligibility criteria
Pathologically or cytologically confirmed diagnosis of HCC with evidence of loca... [+6]
Known additional malignancy that is progressing or that has required active trea... [+4]